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Abstract  
OBJECTIVE: To review the pharmacodynamics and pharmacotherapeutic use of intravenous 
(IV) artesunate for the treatment of severe malaria. 
DATA SOURCES: Literature retrieval was accessed through PubMed (1999 to March 2010) and 
Medline (1996 to March 2010) and the Centers for Disease Control and Prevention (CDC) using 
the search terms artemisinin, artesunate, malaria, and severe malaria.  In addition, reference 
citations from publications identified were reviewed. 
STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the 
data sources were reviewed.  Focus was placed on postmarketing trials examining the safety and 
efficacy of artesunate in comparison to other regimens. 
DATA SYNTHESIS: The treatment of severe malaria requires prompt, safe, and effective 
intravenous antimalarials. Many oral and intravenous agents are available worldwide for the 
treatment of malaria; however, quinindine has been the only option for parenteral therapy in the 
US. Furthermore, lack of this product’s availability and an adverse safety profile has created a 
treatment option gap.  Recently, IV artesunate was approved by the FDA for investigational drug 
use and distribution by the CDC.  Three major studies regarding the use of IV artesunate are 
reviewed in addition to the World Health Organization’s malaria treatment guidelines. While 
there are no published head-to-head trials of IV artesunate versus IV quinidine for severe 
malaria, several international studies comparing intravenous quinine and artesunate conclude that 
artesunate has the highest treatment success with lower adverse events. In addition, other 
literature is reviewed regarding counterfeit and other issues associated with artesunate.   
CONCLUSION: Artesunate, a new antimalarial currently available through the CDC, appears to 
be highly effective, better tolerated than quinidine, and not hampered by accessibility issues. If it 
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were to be FDA approved and commercially available, it would be the preferred agent for the 
treatment of severe malaria in the United States 
KEY WORDS: artesunate, artemisinin, severe malaria 
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Introduction 
Malaria, caused by a protozoan transmitted by Anopheles mosquitoes, is endemic in over 
100 countries, which are visited by more than 125 million international travelers, 64 million of 
them from the U.S., each year.1 Nearly 250 million cases and 1 million deaths are reported 
annually around the world.2  In the United States, approximately 1,500 cases of malaria are 
imported each year, of which nearly two-thirds are caused by Plasmodium falciparum (85% of 
cases from Africa).3 While mortality was low in the 2007 CDC surveillance report, at least 57 
people were classified as having severe malaria that year.  
A malaria infection is categorized as severe when at least one of the following 
complications is present: hypotension, hypoglycemia, severe anemia, hyperparasitemia (>5% or 
250,000 parasites per microliter of blood), hemoglobinuria, jaundice, acidosis, hyperthermia, 
neurologic involvement such as a decreased level of consciousness or seizures, acute respiratory 
distress syndrome, or renal failure. Parasitemia is defined as the percentage of red blood cells 
that are infected on a standard thin blood smear. A review of malaria among U.S. travelers from 
1963 to 2001 found that 185 persons with imported malaria died.4  Common contributors to 
death included lack of malaria chemoprophylaxis, delay in seeking care, misdiagnosis, and 
incorrect antimalarial regimens (i.e., therapy that was inappropriate for the species or region of 
acquisition). Severe malaria is a medical emergency requiring immediate treatment to prevent 
death.  Uncomplicated malaria includes those who are symptomatic, but do not have severe 
disease or evidence of vital organ system dysfunction.  The goal of the treatment of 
uncomplicated malaria is to eradicate the infection whereas the goal of the treatment of severe 
malaria is to first prevent death. 
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In the United States, intravenous (IV) quinidine gluconate (a diastereomer of quinine) is 
the only Food and Drug Administration (FDA)-approved, commercially available medicine for 
the treatment of severe malaria. However, it is in short supply nationally and its use is associated 
with cardiotoxicity and other adverse reactions such as cinchonism (i.e. tinnitus, headache, 
dizziness, diarrhea, and abdominal discomfort), and hypoglycemia. 5, 6,7  
The artemisinin class of antimalarials represents the newest class of medications for the 
treatment of uncomplicated and severe malaria. However, the only commercially available 
artemisinin in the United States is oral artemether (in combination with lumefantrine, brand 
name Coartem®), which was FDA-approved in April 2009 and is indicated for the treatment of 
uncomplicated falciparum malaria. On June 21, 2007, the FDA approved an investigational new 
drug (IND) protocol using IV artesunate for the treatment of severe malaria in the United States. 
The drug is made available by the U.S. Centers for Disease Control and Prevention (CDC) and 
produced by the Walter Reed Army Institute of Research. The World Health Organization 
(WHO) as well as the United Kingdom and Canada recommend artesunate over quinidine for 
treatment of severe malaria.8-10  
Methods for Selection and Assessment of Literature  
 A search of PubMed (1999 to March 2010) and Medline (1996 to March 2010) was 
performed using the key words artesunate, artemisinin, malaria, and severe malaria to identify 
clinical trials and review articles of artesunate in the English language. Focus was placed on 
postmarketing trials of the safety and efficacy of artesunate compared with other regimens, most 
notably quinine, for the treatment of severe malaria. The references of the identified articles were 
reviewed for additional citations. In addition, the CDC’s website (http://www.cdc.gov) was 
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searched for information on the use of artesunate in the United States and to obtain its IND 
protocol.   
Chemistry and Pharmacology 
More than 1500 years ago in China, extracts of qinghao (sweet wormwood, Artemisia 
annua L.) were discovered to have antipyretic properties; subsequent analysis found that a 
component of this extract, qinghaosu, had antimalarial activity. Qinghaosu, better known today 
as artemisinin, is the basis for the newest class of antimalarial medications. Artemisinin is a 
sesquiterpene lactone with an internal peroxide bridge (Figure 1).11 One potential mechanism of 
action of artemisinins involves that endoperoxide bridge. It has been postulated that when 
artemisinins react with Fe2+ in the body, the peroxide bridge is cleaved producing oxygen-
centered free radicals that are subsequently converted to carbon-centered free radicals, which 
may have direct antiparasitic activity.11,12 Evidence also suggests anti-parasitic activity may be 
due to the inhibition of sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA) of P. 
falciparum.13  
 Derivatives of artemisinin—including arteether, artelinate, artemether, artesunate 
(artesunic acid), and dihydroartemisinin—differ from the parent artemisinin by substituted 
groups at position 10 (Figure 1).11 A unique feature of this class of drugs is the ability to kill all 
erythrocytic stages of the malaria parasite, including gametocytes involved in the transmission of 
malaria from person to person.5 In addition, artemisinins inhibit parasite metabolism faster than 
other antimalarials and enhance spleen clearance of infected erythrocytes through reduced 
cytoadherence.11  
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Pharmacokinetics and Pharmacodynamics of IV Artesunate  
Artesunte for intravenous administration is supplied in vials containing 110mg of the 
medication as a sterile dry-filled powder. It is to be reconstituted with 11ml of a sodium 
phosphate diluent which yields a net concentration of 10mg/ml. The resultant solution should be 
gently mixed for five to six minutes and must be administered within one hour. Following 
reconstitution, it should be pushed intravenously over one to two minutes through a 0.8 micron 
hydrophilic polyethersulfone filter.7 
The dosing of IV artesunate has evolved with increased experience with the drug. The 
previously recommended dose of 1.2 mg/kg/day was empirically derived from the absolute 
bioavailability of oral artesunate (F=61%). 14-16  Over time, the dose of IV artesunate for the 
treatment of severe malaria was increased from the previously recommended empiric dose to 2.4 
mg/kg to prevent underdosing in critically ill patients with malaria.15-17 The 2.4 mg/kg per dose 
is now considered the standard of practice. After three days of therapy with IV artesunate, a 
majority of patients will have recovered sufficiently to tolerate and be switched to oral 
medications; however, for those that cannot, IV artesunate can be continued for another four 
days or the patient may be switched to IV doxycycline or IV clindamycin.7  
Artesunate is a prodrug and is rapidly hydrolyzed to dihydroartemisinin (DHA), the 
active constituent and source of the medications antiparasitic activity, directly following 
administration. DHA is then subsequently metabolized by CYP2B6, CYP2C19, and CYP3A4 
enzymes to inactive metabolites.11,16,18 Furthermore, IV artesunate does not need to be dose 
adjusted in patients with either renal or hepatic insufficiency.5 Artemisinins, including 
artesunate, are considered to be the most important antimalarial agents worldwide because of 
their potency (can reduce parasitemia by 10,000 fold in each asexual lifecycle), rapid 
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antiparasitic activity and resolution of symptoms, limited resistance in malaria parasites, and 
good tolerability.5,8,11 However, their use as monotherapy is limited by extremely short half-lives 
of approximately 45 minutes.11 Short courses of monotherapy result in unacceptably high rates of 
recrudescence and raise concerns for drug resistance. Thus, intravenous artesunate, as approved 
for use in the United States, should be used sequentially with a second oral medication such as 
atovaquone-proguanil, doxycycline, clindamycin, or mefloquine after three days of use. Oral 
medications should be initiated on the last day of artesunate therapy, at least four hours after the 
last infusion.7  
In one pharmacokinetic study, Newton et al. found that after administration of 2.4 mg/kg 
of IV artesunate to 11 adult patients with severe malaria, the median plasma concentration at 
time zero was 338 (range 124 to 2557) nmol/L, the median half-life of artesunate was 13.2 
(range 4.8 to 36.6) minutes, and the median time to undetectable drug was 30 (range 15 to 120) 
minutes.16 In this same study, the median Cmax of DHA was 6292 (range 146 to 1646) ng/mL, 
which was reached within 15 minutes by all patients, and the median half-life of DHA was 20.4 
(range 8.4 to 52.2) minutes. Median DHA clearance was 5.6 (range 2.9 to 16.6) L/kg/hr. One 
patient with severe malaria died in this study with only median values for all pharmacokinetic 
parameters.16  
Clinical Studies and Guidelines  
Clinical studies have evaluated the safety and efficacy of artesunate in comparison to 
quinine in patients with severe malaria. Results from selected trials are summarized below as 
well as in Table 1.19-23 A brief summary of the WHO malaria treatment guidelines as they pertain 
to artesunate are also included.  
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 Newton et al. compared the safety and efficacy of IV quinine to IV artesunate in a 
randomized, open-labeled study involving 113 persons ≥ 15 years of age in Western Thailand 
with slide confirmed P. falciparum parasitemia of > 0.1% and that were determined to have 
severe malaria.21 42% of all patients in this study had a parasitemia level of > 10%. Pregnant 
women, those with contraindications to study medications, and those who received artesunate, 
quinine, or mefloquine in the previous 24 hours were excluded from the study. Patients in the 
artesunate group (n=59) received 2.4 mg/kg on entry, 1.2 mg/kg 12 hours later, and then 1.2 
mg/kg/day. Patients in the quinine group (n=54) received 20 mg/kg of medication administered 
IV over four hours followed by 10mg infused over two hours and given three times daily. There 
was no mention of specifically when either artesunate or quinine was first initiated (i.e. on 
hospital admission or on study enrollment) by the investigators. This may have lead to delays in 
treatment thus impacting overall mortality rates in this study. However, when patients were able 
to tolerate oral medications, they were switched accordingly to either oral artesunate or oral 
quinine. 
Overall, 17% of the patients died in this study. Death was attributable to pulmonary 
edema/acute respiratory distress syndrome, cardiorespiratory arrest, hypotension, oliguria, and/or 
gastrointestinal tract bleeding. Seven patients (12%) in the artesunate group and 12 patients 
(22%) in the quinine group died, RR=0.53 (0.23-1.26), p=0.22. Median time to death was also 
shorter in the quinine group (21 hours) than in the artesunate group (48 hours), p=0.02. In 
addition, the mean time for parasitic clearance in the quinine group (76 hours) was longer than in 
the artesunate group (62.5 hours), p=0.019. The investigators concluded that artesunate is at least 
as effective as quinine in the treatment of severe malaria and is likely safer, as fewer patients 
receiving artesunate developed hypoglycemia compared with those receiving quinine (10.2% 
Page 11 of 28 
 
versus 28%, p=0.028). Despite these initial findings, however, larger trials were deemed to be 
needed to evaluate the benefit of artesunate in reducing mortality.  
 The South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT; Dondorp, et al) 
compared IV artesunate to IV quinine in a randomized, open-labeled, multicentered trial among 
1,461 patients in Bangladesh, India, Indonesia, and Myanmar (Burma) in perhaps the largest and 
most definitive trial to date.23 Patients were enrolled if they were older than two years of age, had 
a positive blood antigen test for Plasmodium falciparum histadine rich protein 2 (HRP2), and 
had a diagnosis of  severe P. falciparum malaria by the attending physician. Individuals were 
excluded if they had received a full treatment with quinine or an artemisinin derivative for more 
than 24 hours before admission or had a known allergy to a study medication. Patients 
randomized to the artesunate group (n=730) received 2.4 mg/kg on admission and then again at 
12 and 24 hours followed by daily administration of IV artesunate until oral therapy could be 
tolerated. Those receiving quinine (n=731) received 20 mg/kg infused over 4 hours followed by 
10 mg/kg infused over 2 to 8 hours 3 times daily until oral therapy could be started. The study’s 
primary endpoint was mortality from severe malaria. 
Overall, 19% of the patients in this trial died; mortality was significantly lower in the 
artesunate group (15%) than in the quinine group (22%), OR=0.60 (0.45 to 0.79), p=0.0002. 
Reduction in mortality occurred primarily after the first 24 to 48 hours after treatment began 
which indicates that prompt treatment of severe malaria is vitally important. There was a 
statistically significant reduction in mortality associated with artesunate in adults (16% versus 
24%, P < 0.0005) but not in children (5% versus 11%, P=0.15). The small number of children 
enrolled (n=202) may have contributed to this study’s inability to detect a statistically significant 
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difference; however, this does not rule out a potentially clinically significant effect of artesunate 
when used in children.  
Patients with parasitemia > 10% on admission (defined as hyperparasitemia by the study 
investigators) had a greater reduction in mortality with artesunate as compared to non-
hyperparasitemic patients, OR=0.34 (0.17 to 0.69), p=0.001. The calculated number needed to 
treat (NNT) to save one life with artesunate ranged from 11.1 to 20.2. Among surviving patients, 
the incidence of hypoglycemia was greater in the quinine group (3%) than in the artesunate 
group (<1%), p=0.009. Based on these results, the investigators suggest that artesunate should be 
the drug of choice to treat severe malaria in adults. A statistically significant effect was not 
observed in children and therefore the same conclusion could not be reached as in adults; 
however, the drug did show benefit in this population.   
In a 2007 Cochrane review, Jones et al. conducted a systematic literature review to 
evaluate the use of artesunate versus quinine for the treatment of severe malaria.24 Six 
randomized controlled trials were identified (Anh 1989, Hien 1992, Anh 1995, Phuong 1997, 
Newton 2003, and Dondorp 2005) for a total enrollment of 1,938 individuals (1,664 adults and 
274 children) with severe malaria as determined by study investigators. Phuong, et al. were the 
only investigators to enroll only children; they randomized treatment to either artemisinin 
suppositories, IM artesunate, or IV quinine.22 All six studies were conducted in Asia 
(Bangladesh, Myanmar, India, Indonesia, Thailand, and Vietnam); the primary outcome measure 
was mortality from severe malaria. From their review of these trials, the authors concluded that 
artesunate was superior to quinine in reducing death from severe malaria (RR 0.62, 0.51-0.75). 
Furthermore, the authors stated that artesunate should be the drug of choice for the treatment of 
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severe malaria in adults; however, the same conclusion could not be reached for children as a 
significant benefit with artesunate treatment could not be found similar to the SEAQUMAT trial.   
 According to the 2005 WHO malaria treatment guidelines, IV artesunate is the drug of 
choice for the treatment of severe malaria in adults. However, there is insufficient data to 
recommend the use of artesunate over other agents for the treatment of severe malaria in 
children.8 This recommendation is based largely on the results of SEAQUAMAT which showed 
a statistically significant treatment benefit with artesunate in adults but not in children.23 
Adverse Reactions  
Artemisinin derivatives, including artesunate, have been used to treat cases of malaria 
worldwide with few reported severe adverse reactions. Compared with quinine and quinidine, 
they are considered less toxic and have fewer side effects.7,25,26 While formal human toxicity data 
are limited, evidence and surveillance data suggest that this medication class is safe to use in 
adults and children.7 Furthermore, reports of severe allergic reactions are rare, although a small 
number of patients (approximate risk of 1 in 3,000 patients) have had a urticarial rash with 
additional symptoms such as hypotension, pruritis, edema, dyspnea.21,27 Common adverse 
reactions to IV artesunate include dizziness, nausea, vomiting, anorexia, diarrhea, transient 
reticulocytopenia, and a bitter or metallic taste during infusion; however, discerning between 
adverse effects and symptoms from severe malaria may be difficult.7,21,25,28 At doses of 6mg/kg, 
elevations in ALT and BUN have been observed and at doses of 15mg/kg, bradycardia may 
occur.7   
Precautions and Contraindications 
Intravenous artesunate is considered to be widely tolerated by almost all patients at 
recommended dosages.7 Concerns have been raised however regarding its potential to interfere 
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with normal cardiac conduction since high intramuscular doses of other artemisinin derivates 
(e.g. artemether and artemotil) have caused QT prolongation in animal models which raise the 
concern of a class effect.  
To evaluate the effect intravenous artesunate may have on cardiac conduction, Maude et 
al. studied the electrocardiograms (EKGs) of patients ≥ 16 years old with severe malaria on 
admission that were given intravenous artesunate and then again after the last dose of artesunate. 
Patients were initially given IV artesunate at 2.4 mg/kg, followed by 2.4 mg/kg at 12 and 24 
hours and then every 24 hours thereafter. EKG’s were recorded at time 0 (prior to artesunate 
therapy) and then at 10, 30, 60, 120, and 240 minutes following administration of artesunate. 
Blood pressure, heart rate, and temperature were also measured at these time points. The primary 
outcome in this study was a change in QTc before and after artesunate with a significant change 
in QTc being defined as > 500ms in an individual patient or a mean increase of > 25% in all 
patients. No significant change in the mean QTc was observed nor did any patient have an 
increase in QTc of > 25% above baseline. The investigators therefore concluded that intravenous 
artesunate does not have a consistent cardiovascular or electrocardiographic effect when 
administered.29  
Artemisinin-induced neurotoxicity in humans has also been a concern because this side 
effect has been observed in animal models when either very high doses (range 25 to 250 
mg/kg/day) or when the lipophilic artemisinins (e.g, artemether and arteether) have been 
administered. Such neurotoxic effects in laboratory animals may include auditory dysfunction, 
ataxia, hypersalivation, as well as deleterious effects on the brainstem.7,25  It is important to note 
that these or other CNS related side effects have not been directly associated with any 
artemisinin, including artesunate, in humans at currently recommended doses. In addition, severe 
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malaria itself can cause deficits in neurological functioning; therefore, differentiating between 
symptoms of severe malaria and adverse drug reactions from treatment may be difficult. The 
only known contraindication to artesunate is a known allergic or anaphylaxic reaction to the 
medication.7 While there is little known about drug-drug interactions with IV artesunate, its short 
half-life of less than two hours suggests this is not a significant concern.  
Special Populations – Pediatrics 
 Children, particularly those residing in areas of high malaria transmission (e.g. Africa), 
are at risk for developing severe malaria due to their limited immunity from previous exposures. 
Despite positive findings from SEAQUAMAT in the adult population, the efficacy of artesunate 
for the treatment of severe malaria in the pediatric population remains to be clearly established. 
In SEAQUAMAT, 202 children (age < 15 years) were enrolled. While fewer died in the 
artesunate group than in the quinine group (5 vs. 11% respectively), the results were not 
statistically significant. Therefore, the authors could not conclude that artesunate was superior to 
quinine; however, the medication did appear to be effective in the pediatric population for the 
treatment of severe malaria as mortality was less in the artesunate group. It is important to note 
that the presentation of malaria may also differ in children than in adults and childhood mortality 
from malaria tends to occur within the first 24 hours after treatment initiation giving 
antimalarials less time to work.23 Large-scale studies, similar to SEAQUAMAT, are therefore 
needed to evaluate the use and efficacy of IV artesunate in the pediatric population. One such 
study, AQUAMAT (an open labeled randomized comparison of injectable artesunate and quinine 
in children with severe falciparum malaria in Africa), is currently underway. Artesunate is 
available to children in the U.S. under IND protocol despite the lack of statistical evidence 
demonstrating superiority over quinine.   
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Special Populations – Pregnancy  
In pregnant animals given IV artesunate, fetal resorption and abortion, cardiac 
malformations, and skeletal defects have been observed. There is a thus theoretical risk of 
artesunate causing teratogenicity in humans because of the medication’s ability to cross the 
placenta. However, in trials conducted in Thailand, the Gambia, and Sudan that primarily 
involved women in their second or third trimester of pregnancy (n=2045) who were given either 
artesunate alone or in combination with other antimalarials found that birth weight, duration of 
gestation, placenta weight, and congenital abnormality rates were not statistically different than 
in the community.7 While the number of pregnant women treated with artesunate remains 
relatively low, continuous observations will need to be made to better assess the risk of 
artesunate teratogenicity.  
Currently, the WHO recommends the use of artesunate over quinine in pregnancy in the 
second and third trimesters due to higher rates of mortality versus non-pregnant adults in 
addition to the risk for fetal mortality and premature birth.8 Hypoglycemia is also a common 
complication during these stages of pregnancy and quinine use may further cause hypoglycemia 
to occur. In the first trimester, the severity of hypoglycemia is not as great and the risks of using 
artemisinin derivatives appear to be greater; therefore, the risk of using artesunate during the first 
trimester of pregnancy should be weighed against the potential for complications from severe 
malaria. During the first trimester, the WHO advocates the use of either artesunate or quinine.8  
Therapeutic Issues and Controversies  
Access to IV Artesunate in the United States  
While IV artesunate itself is not currently approved by the FDA, it is available in the 
United States through the CDC under IND protocol #76,725 in collaboration with the Walter 
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Reed Army Institute of Research. Under this IND, IV artesunate is available only for the 
treatment of patients with severe malaria (see table 2 for eligibility criteria).7  
 Artesunate is available from the CDC (see www.cdc.gov/malaria for details). Depending 
on the time of day and distance to the treatment facility, artesunate is sent by the fastest method 
available including ground courier or commercial flight. Once received, artesunate should be 
administered as soon as possible. If during therapy a serious adverse drug reaction is 
experienced, it must be reported to the CDC within 24 hours by telephone and a Serious Adverse 
Event Report Form must also be submitted to the CDC within 10 days.7 Currently, 
approximately 70 patients have been successfully treated with IV artesunate in the United States 
since August 2007 (CDC unpublished data).    
Resistance to Artesunate  
The use of IV artesunate as monotherapy for severe malaria is limited as discussed 
previously in the pharmacokinetics and pharmacodynamics section. While resistance to 
artesunate and to other artemisinin derivates appears to be minimal at present, two recent reports 
of P. falciparum resistance in Western Cambodia raise concern that resistance to this important 
class of medication may occur in the future.30,31    
Counterfeit Medications  
Although any type of medicine may be counterfeited, artesunate has been 
disproportionately targeted internationally due to the relatively higher retail price and high 
demand. 32,33 A counterfeit medicine is one that is deliberately and fraudulently mislabeled with 
respect to identity and/or source. Counterfeit products may include products with the correct 
ingredients or with the wrong ingredients, without active ingredients, with insufficient active 
ingredients, or with fake packaging. 34,35 Counterfeit artesunate, predominantly in Southeast 
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Asia, has been directly implicated in numerous deaths. 33,36 Travelers to developing countries 
should be discouraged from acquiring artesunate while overseas due to the high risk of receiving 
a counterfeit medicine. If medicines to treat malaria will likely be needed, it is preferable to fill a 
prescription for a reliable supply at a pharmacy in the industrialized country prior to traveling.  
Dosage and Administration  
Per its IND protocol, artesunate for the treatment of severe malaria should be 
administered intravenously at a dose of 2.4 mg/kg initially and then repeated at 12, 24, and 48 
hours later for a total of four doses.7 It is worth noting that this dosing regimen is the same as 
that used in SEAQUAMAT.23 After three days of therapy, the patient should be switched to an 
oral antimalarial agent to ensure a curative treatment.  
Summary  
For years, IV quinidine has been the sole drug in the United States for the treatment of 
severe malaria. However, its limited availability and the need for continuous cardiac monitoring 
underscore the need for additional options. The artemisinin class of medications is available 
worldwide, has been effective for the treatment of severe malaria, yet is not routinely available in 
the United States. Intravenously administered arartesunate is therefore necessary to provide 
another treatment option for severe malaria in light of the limitations with the use of quinidine. 
Since artesuante is distributed only by the CDC, an FDA-approved, commercially available 
formulation with widespread availability would be a welcome addition to the U.S. antimalarial 
formulary. 
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Table 1: Selected Comparative Treatment Studies  
Trial (Year) and 
Reference  
Participants  Interventions  Outcomes measured Key results for IV 
artesunate   
Hien (1992)19 Severe 
malaria 
(n=79) 
Artesunate 60mg IV at 0, 
4, 24, and 48 hrs (n=31) 
 
Artemisinin suppositories 
600mg initially and at 4 
hrs, then 400mg at 24, 
32, 48, and 56 hrs (n=18) 
 
Quinine 500mg IV over 4 
hrs then 500mg IV Q8H 
until able to swallow then 
500mg PO Q8H until day 
14 (n=30) 
 Fever clearance 
time 
 Parasite clearance 
time of 50% 
 Mortality  
 
 Fever clearance 
time faster than 
quinine (39 vs. 78 
hrs) 
 Faster parasite 
clearance than 
quinine (5.4 vs. 
16.6 hrs)  
 16.5% mortality 
vs. 26.7% for 
quinine  
 
 
Phuong (1997)22 Age < 15 
years old 
with severe 
malaria 
(n=109) 
Artemisinin suppositories 
40mg/kg initially then 
20mg/kg at 4, 24, 48, and 
72 hrs. (n=37) 
 
Artesunate 3mg/kg IM at 
 Mortality 
 Number that 
survived with 
neurological 
sequelae  
 Fever clearance 
 11% mortality vs. 
14% for quinine  
 Fever clearance 
time similar for 
artesunate and 
quinine (84% and 
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Trial (Year) and 
Reference  
Participants  Interventions  Outcomes measured Key results for IV 
artesunate   
0 then 2mg/kg IM at 12, 
24, 48, and 72 hrs (n=37) 
 
Quinine 20mg/kg IV at 0 
then 10mg/kg IV Q8H up 
to day 7 (n=35) 
time  
 Resolution of coma 
 Parasite clearance 
time of 50% 
 Hypoglycemia  
 
81%) 
 Parasite clearance 
time of 5.7 hrs for 
artesunate vs. 13.2 
for quinine  
 16% 
hypoglycemia vs 
26% for quinine  
Newton (2003)21 Age > 15 
years old 
with severe 
malaria 
(n=113) 
Artesunate 2.4mg/kg IV 
at 0 then 1.2mg/kg at 12 
and at every 24 hrs until 
able to swallow then 
12mg/kg PO Q24H over 
7 days (n=59) 
 
Quinine 20mg/kg over 4 
hrs followed by 10mg 
over 2 hrs infused three 
times daily until able to 
swallow (n=54) 
 Fever clearance 
time 
 Parasite clearance 
time of 50% 
 Time to regain full 
conscious  
 Death  
 Hypoglycemia 
 Adverse effects  
 Mean parasitic 
clearance time of 
62.5 hrs for 
artesunate and 76 
hrs for quinine  
 10.2 % 
hypoglycemia in 
artesunate group 
vs. 28% in the 
quinine group  
 Reduced mortality 
in artesunate 
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Trial (Year) and 
Reference  
Participants  Interventions  Outcomes measured Key results for IV 
artesunate   
group vs quinine 
group(12% vs 
22%)  
Mohanty (2004)20 Pediatric 
cases with 
severe 
malaria 
(n=80) 
Artesunate 2.4mg/kg IV 
at 0 then 1.2mg/kg at 6 
hrs; then every 24 hrs for 
5 days (n=40) 
 
Quinine 20mg/kg IV at 0, 
then 10mg/kg IV Q8H 
until able to swallow then 
10mg/kg PO Q8H until 
day 7 (n=40) 
 Fever clearance 
time 
 Parasite clearance 
time of 50% 
 Time to regain full 
consciousness  
 Death  
 
 Time to regain full 
consciousness was 
50 hrs in 
artesunate group 
vs 70 hrs for 
quinine  
 Fever clearance 
time of 43.5 hrs 
for artesunate and 
62 hrs for qunine 
 Parasitic clearance 
time of 42 hrs for 
artesunate and 52 
hrs for qunine 
 12.5% mortality in 
artesunate group, 
20% mortality in 
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Trial (Year) and 
Reference  
Participants  Interventions  Outcomes measured Key results for IV 
artesunate   
quinine group    
Dondorp 
(SEAQUAMAT) 
(2005)23 
Individuals > 
2 years old 
with severe 
malaria 
(n=1461) 
Artesunate 2.4mg/kg IV 
at 0, 12, and 24 hrs then 
2.4mg/kg IV Q24H  until 
able to swallow then 
2mg/kg PO until day 7 
(n=730) 
 
Quinine 20mg/kg infused 
over 4 hours followed by 
10mg/kg over 2 to 8 
hours three times daily 
(n=731) 
 
 In hospital death 
 Death within 48 hrs  
 Death after 48 hrs  
 Neurological 
sequelae  
 Time to discharge  
 Hypoglycemia  
 In hospital death 
15% in artesunate 
group, 22% in 
quinine group 
 Death after 48 hrs 
was 6% in the 
artesunate group 
and 12% for the 
quinine group  
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Table 2: Qualifications to receive intravenous artesunate per investigational new drug protocola, b  
Category Eligibility Criteria 
Clinical and Laboratory  Diagnosis of P. falciparum or other Plasmodium species by 
microscopy 
 Strong clinical suspicion of severe malaria without a timely 
and reliable microscopic diagnosis  
Parenteral Therapy 
Required 
 Inability to take oral medications 
 High density parasitemia of > 5%  
 Severe malaria  
IV Artesunate Preferred   IV artesunate more readily available than IV quinidine 
 Quinidine failure documented as parasitemia of > 10% of 
baseline at 48 hours after initiation  
 Quinidine intolerance defined as 
o QRS widening by ≥ 50% 
o QT interval > 0.6 seconds 
o QTc interval prolonged by >25% of baseline 
o Persistent hypotension despite IV fluids 
o Development of quinidine ADR  
 Contraindication to quinidine defined as  
o Allergy to quinidine or cinchona alkaloids  
o Thrombocytopenic purpura with previous therapy 
o AV junctional or idioventricular pacemaker (with 
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Category Eligibility Criteria 
no atrial activity) 
o AV block 
o Left bundle branch block or other intraventricular 
conduction defects  
o Digitalis toxicity  
o Myasthenia gravis  
Adapted from reference 7  
a. Patients must meet at least one eligibility criteria from each category to qualify for IV 
artesunate therapy  
b. To obtain IV artesunate, the treating physician must first call the CDC Malaria Hotline 
at 770-488-7788 (open from 9:00am to 5:00pm eastern time) to determine patient 
eligibility. After hours, clinicians may call 770-488-7100 and request to speak with a 
CDC Malaria Branch clinician. 
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